jianhua Sun

Dr. jianhua Sun


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
XYXiao-Xia Yan
Xiao-Xia Yan
HLHai-Long Li
Hai-Long Li
YZYi-Ting Zhang
Yi-Ting Zhang
SWShou-Yan Wu
Shou-Yan Wu
HLHeng-Lei Lu
Heng-Lei Lu
LGLikun Gong
Likun Gong

13 May 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SWShouyan Wu
Shouyan Wu
HLHenglei Lu
Henglei Lu
WWWenjie Wang
Wenjie Wang
LSLuyao Song
Luyao Song
MLMeng Liu
Meng Liu
LGLikun Gong
Likun Gong
Acute liver injury (ALI) has multiple causes and results in liver dysfunction. Severe or persistent liver injury eventually leads to liver failure and even death. Pregnane X receptor (PXR)-null mice present more severe liver damage and lower rates of autophagy. 18β-glycyrrhetinic acid (GA) has been proposed as a promising hepatoprotective agent. We hypothesized that GA significantly alleivates D-GalN/LPS-induced ALI, which involved in PXR-mediated autophagy and lysosome biogenesis. We found that GA can significantly decrease hepatocyte apoptosis and increase the hepatic autophagy marker LC3-B. Ad-mCherry-GFP-LC3 tandem fluorescence, RNA-seq and real-time PCR indicated that GA may stabilize autophagosomes and lysosomes and inhibit autophagosome–lysosome fusion. Simultaneously, GA markedly activates PXR, even reversing the D-GalN/LPS-induced reduction of PXR and its downstream genes. In contrast, GA has a weak protective effect in pharmacological inhibition of PXR and PXR-null mice, which significantly affected apoptosis- and autophagy-related genes. PXR knockout interferes with the stability of autophagosomes and lysosomes, preventing GA reducing the expression of lysosomal genes such as Cst B and TPP1, and suppressing autophagy flow. Therefore, we believe that GA increases autophagy by inhibiting autophagosome–lysosome fusion and blocked autophagy flux via activation of PXR. In conclusion, our results show that GA activates PXR to regulate autophagy and lysosome biogenesis, represented by inhibiting autophagosome–lysosome fusion and stabilization of lysosome. These results identify a new mechanism by which GA-dependent PXR activation reduces D-GalN/LPS-induced acute liver injury.

17 March 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
NLNan Liu
Nan Liu
HLHui Long
Hui Long
JSjianhua Sun
jianhua Sun
HLHuan Li
Huan Li
YHYunting He
Yunting He
LGLikun Gong
Likun Gong

8 December 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
YLYiru Long
Yiru Long
RCRunqiu Chen
Runqiu Chen
XYXiaolu Yu
Xiaolu Yu
YTYongliang Tong
Yongliang Tong
XPXionghua Peng
Xionghua Peng
Likun GongLikun Gong
Likun Gong
CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is known to be a regulator of membranal programmed death ligand 1 (PD-L1) stability and a factor associated with malignancy progression, but the effects and mechanisms of CMTM6 on tumor growth, as well as its potential as a target for therapy, are still largely unknown. Here, we show that CMTM6 expression increased with tumor progression in both patients and mice. Ablation of CMTM6 significantly reduced human and murine tumor growth in a manner dependent on T-cell immunity. Tumor CMTM6 suppression broke resistance to immune-checkpoint inhibitors and remodeled the tumor immune microenvironment, as specific antitumor cytotoxicity was enhanced and contributed primarily to tumor inhibition. Without the PD-1/PD-L1 axis, CMTM6 suppression still significantly dampened tumor growth dependent on cytotoxic cells. Furthermore, we identified that CMTM6 was widely expressed on immune cells. T-cell CMTM6 levels increased with sustained immune activation and intratumoral immune exhaustion and affected T cell–intrinsic PD-L1 levels. Host CMTM6 knockout significantly restrained tumor growth in a manner dependent on CD8+ T cells and not entirely dependent on PD-L1. Thus, we developed and evaluated the antitumor efficacy of CMTM6-targeting adeno-associated virus (AAV), which effectively mobilized antitumor immunity and could be combined with various antitumor drugs. Our findings reveal that both tumor and host CMTM6 are involved in antitumor immunity with or without the PD-1/PD-L1 axis and that gene therapy targeting CMTM6 is a promising strategy for cancer immunotherapy.

16 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
JLJiangling Lu
Jiangling Lu
YLYiru Long
Yiru Long
JSjianhua Sun
jianhua Sun
Likun GongLikun Gong
Likun Gong
Herpes B virus is a biosafety level 4 pathogen and widespread in its natural host species, macaques. Although most infected monkeys show asymptomatic or mild symptoms, human infections with this virus can cause serious neurological symptoms or fatal encephalomyelitis with a high mortality rate. Herpes B virus can be latent in the sensory ganglia of monkeys and humans, often leading to missed diagnoses. Furthermore, the herpes B virus has extensive antigen crossover with HSV, SA8, and HVP-2, causing false-positive results frequently. Timely diagnosis, along with methods with sensitivity and specificity, are urgent for research on the herpes B virus. The lack of a clear understanding of the host invasion and life cycle of the herpes B virus has led to slow progress in the development of effective vaccines and drugs. This review discusses the research progress and problems of the epidemiology of herpes B virus, detection methods and therapy, hoping to inspire further investigation into important factors associated with transmission of herpes B virus in macaques and humans, and arouse the development of effective vaccines or drugs, to promote the establishment of specific pathogen-free (SPF) monkeys and protect humans to effectively avoid herpes B virus infection.

21 June 2024 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
XHXiang He
Xiang He
JLJiang-Ling Lu
Jiang-Ling Lu
WLWen-Feng Liao
Wen-Feng Liao
YLYi-Ru Long
Yi-Ru Long
XZXing Zhang
Xing Zhang
YYYi-Fu Yang
Yi-Fu Yang